JPWO2020238998A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2020238998A5
JPWO2020238998A5 JP2021569941A JP2021569941A JPWO2020238998A5 JP WO2020238998 A5 JPWO2020238998 A5 JP WO2020238998A5 JP 2021569941 A JP2021569941 A JP 2021569941A JP 2021569941 A JP2021569941 A JP 2021569941A JP WO2020238998 A5 JPWO2020238998 A5 JP WO2020238998A5
Authority
JP
Japan
Prior art keywords
seq
antibody
set forth
chain variable
variable region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021569941A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022533855A (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2020/092766 external-priority patent/WO2020238998A1/en
Publication of JP2022533855A publication Critical patent/JP2022533855A/ja
Publication of JPWO2020238998A5 publication Critical patent/JPWO2020238998A5/ja
Pending legal-status Critical Current

Links

JP2021569941A 2019-05-30 2020-05-28 抗TrkA抗体及びその使用 Pending JP2022533855A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201910464016.0 2019-05-30
CN201910464016 2019-05-30
PCT/CN2020/092766 WO2020238998A1 (en) 2019-05-30 2020-05-28 Anti-trka antibodies and uses thereof

Publications (2)

Publication Number Publication Date
JP2022533855A JP2022533855A (ja) 2022-07-26
JPWO2020238998A5 true JPWO2020238998A5 (zh) 2022-08-02

Family

ID=73506735

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021569941A Pending JP2022533855A (ja) 2019-05-30 2020-05-28 抗TrkA抗体及びその使用

Country Status (7)

Country Link
US (1) US20220204630A1 (zh)
EP (1) EP3976657A4 (zh)
JP (1) JP2022533855A (zh)
CN (2) CN114230663B (zh)
AU (1) AU2020281378A1 (zh)
TW (1) TW202110888A (zh)
WO (1) WO2020238998A1 (zh)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023549300A (ja) * 2020-11-20 2023-11-24 サンシャイン・レイク・ファーマ・カンパニー・リミテッド ヒト化抗TrkA抗体及びその使用
CN117264068A (zh) * 2021-02-28 2023-12-22 熙源安健医药(上海)有限公司 抗TrkA抗体或其抗原结合片段、其制备方法和应用
WO2023125477A1 (en) * 2021-12-28 2023-07-06 4B Technologies (Beijing) Co., Limited TrkA ANTIBODY AND APPLICATION THEREOF
CN115611985A (zh) * 2022-10-27 2023-01-17 合肥天港免疫药物有限公司 抗cd3的抗体及其应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0326780D0 (en) * 2003-11-18 2003-12-24 Imp College Innovations Ltd Biological materials and uses thereof
US8911726B2 (en) * 2004-09-22 2014-12-16 Kyowa Hakko Kirin Co., Ltd Stabilized human Igg4 antibodies
ITRM20050290A1 (it) * 2005-06-07 2006-12-08 Lay Line Genomics Spa Uso di molecole in grado di inibire il legame tra ngf e il suo recettore trka come analgesici ad effetto prolungato.
DK2252633T3 (da) * 2008-02-04 2013-11-11 Lay Line Genomics Spa Anti-TrkA antistoffer og derivater deraf
US8183346B2 (en) * 2008-12-05 2012-05-22 Eli Lilly And Company Anti-ferroportin 1 monoclonal antibodies and uses thereof
DK2766392T3 (da) * 2011-10-10 2019-10-07 Xencor Inc Fremgangsmåde til oprensning af antistoffer
JP2015520182A (ja) * 2012-06-08 2015-07-16 グレンマーク ファーマシューティカルズ, エセ.アー. アミノ酸置換を有するヒト化抗TrkA抗体
EP2674439B1 (en) * 2012-06-13 2017-02-01 Rottapharm Biotech S.r.l. Anti-TrkA antibodies, derivatives and uses thereof
MA41097A (fr) * 2014-12-05 2017-10-10 Glenmark Pharmaceuticals Sa Anticorps anti-trka à propriétés inhibitrices améliorées et dérivés desdits anticorps destinés à être utilisés pour traiter les douleurs osseuses
US20190184015A1 (en) * 2016-09-02 2019-06-20 European Molecular Biology Laboratory Irradiation treatment of neurological sensations by photoablation
EP3596130A4 (en) * 2017-03-14 2020-12-30 Sunshine Lake Pharma Co., Ltd. DOUBLE TARGET FUSION PROTEINS WITH FC PORTION OF AN IMMUNE LOBULIN

Similar Documents

Publication Publication Date Title
JP7304375B2 (ja) 血清アルブミンに結合するタンパク質
JP7417421B2 (ja) 改善された血清アルブミン結合性免疫グロブリン単一可変ドメイン
JP7041516B2 (ja) 共通軽鎖を有する二重特異性抗体又は抗体混合物
US20230060574A1 (en) Serum albumin binders
JP7195142B2 (ja) 改善された血清アルブミン結合性免疫グロブリン可変ドメイン
JP6779252B2 (ja) IL−1βへの結合メンバー
EP2934584B1 (en) Anti-gdf15 antibodies
US10703813B2 (en) Anti IL-34 antibodies
JP2020506898A (ja) 改善された血清アルブミン結合剤
RU2011135422A (ru) Человеческие анти-il-6 антитела с пролонгированным периодом выведения in vivo и их применение при лечении онкологических, аутоиммунных заболеваний и воспалительных заболеваний
US11780916B2 (en) GIPR antibody and GLP-1 fusion protein thereof, and pharmaceutical composition and application thereof
TWI734410B (zh) 阻礙血管內皮脂酶之酵素活性的人類化單株抗體
JP2019505565A5 (zh)
CN110402254B (zh) 针对fgfr1的单克隆抗体
JPWO2020238998A5 (zh)
JP2019509714A5 (zh)
CN113444176B (zh) Ngf的抗体及其应用
CN102863533A (zh) 抗体人源化改造方法
KR20220119393A (ko) 약학 조성물, 이의 제조 방법 및 이의 용도
RU2800370C2 (ru) Антитело к gipr и его слитый с glp-1 белок, а также фармацевтическая композиция на его основе и его применение
WO2018095932A1 (en) Monoclonal antibody directed to fgfr1
CN114516917B (zh) 人源化抗TrkA的抗体及其应用
TW202233683A (zh) 針對wnt受體ryk之抗體變異體